CLGN

$0.60

Post-MarketAs of Mar 17, 8:00 PM UTC

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.60
Potential Upside
5%
Whystock Fair Value$0.63
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company'...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-92.74%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.34

Recent News

Simply Wall St.
Feb 8, 2026

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Turn A Profit?

We feel now is a pretty good time to analyse CollPlant Biotechnologies Ltd.'s ( NASDAQ:CLGN ) business as it appears...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Feb 6, 2026

CollPlant to sell 1.6M ordinary shares at $1.25 in registered direct offering

CollPlant (CLGN) Biotechnologies announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1.6M of the company’s ordinary shares at a purchase price of $1.25 per share in a registered direct offering. In addition, in a concurrent private placement, the company will issue unregistered series A warrants to purchase up to 1.6M ordinary shares and unregistered series B warrants to purchase up to 1.6M ordinary shares. The series A warrants will have an exe

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 13, 2025

Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Oct 3, 2025

One CollPlant Biotechnologies Insider Raised Their Stake In The Previous Year

From what we can see, insiders were net buyers in CollPlant Biotechnologies Ltd.'s ( NASDAQ:CLGN ) during the past 12...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
May 30, 2025

Discover May 2025's Top Penny Stocks

Over the last 7 days, the U.S. market has risen by 1.2%, contributing to a 12% increase over the past year, with earnings anticipated to grow by 14% annually. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever; these stocks can provide a mix of affordability and growth potential when paired with strong financials. Below, we'll explore three penny stocks that stand out for their financial strength and resilience in today's...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.